Targovax ASA: Immunotherapy with ONCOS-102 show potential to activate immunologically silent tumors and reduce local immune suppression in advanced tumors
Targovax [TRVX.OTC] will present at the SITC 2015 - an annual event of The Society for Immunotherapy of Cancer in Maryland, USA.
SITC is the world's leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy.
On Friday 6 November, Vice President Pre-clinical Research & Clinical Science of Targovax, Sari Pesonen, will present a poster on immune biomarker data from a phase I study, which suggests that local immunotherapy with ONCOS-102 has the potential to activate immunologically silent tumors and reduce local immune suppression in advanced tumors.
Dmitriy Zamarin, Assistant Attending Physician, Gynecologic Medical Oncology and Immunotherapeutics Services at Memorial Sloan Kettering Cancer Center (MSK) will give an oral presentation on the same data, the day after.
For more information, please contact:
Chief Financial Officer
+47 90 65 65 25
Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapies for cancer patients.
Targovax is a leader in the immuno-oncology field born out of the merger in July 2015 of Targovax and Oncos Therapeutics, The company headquarter is in Oslo with another office in Helsinki.
Targovax is developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient's own immune system to fight the cancer.